156755-24-7

Upstream product

• 621-82-9 Cinnamic acid 
• 106-41-2 4-bromo-phenol 
• 140-10-3 (E)-3-phenylacrylic acid 
• 67-56-1 methanol 
• 156755-23-6 6-bromo-4-phenyl-3,4-dihydro-2H-chromen-2-one 
• 100-44-7 benzyl chloride 

Downstream Products

• 156755-35-0 methyl 4-(benzyloxy)-3-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]benzoate 
• 950773-38-3 R-(-)-[3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl]diisopropylamine 
• 207679-81-0 (R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)-phenol 
• 286930-02-7 fesoterodine 
• 286930-03-8 fesoterodine fumarate 
• 156755-37-2 {4-(benzyloxy)-3-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]phenyl}methanol 
• 250214-37-0 (+/-)-toluene-4-sulphonic acid 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl ester 
• 156755-33-8 (R)-4-(benzyloxy)-3-(3-(diisopropylamino)-1-phenylpropyl)benzoic acid hydrochloride 
• 754159-68-7 4-(benzyloxy)-3-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]benzoic acid 
• 1135493-18-3 C₂₀H₁₈O₈*C₂₈H₃₄BrNO 
• 1361197-27-4 3-(2-(benzyloxy)-5-bromophenyl)-3-phenylpropyl methanesulfonate 
• 1429299-06-8 R-(-)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid (1S,2R)-ephedrine salt 
• 1185739-54-1 (+/-)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid 
• 286930-03-8 2-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate fumarate 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF FESOTERODINE OR ITS SALTS

The present invention relates to a process for the preparation of fesoterodine or its salts.

PROCESSES FOR THE PREPARATION OF FESOTERODINE

The invention relates to improved process for the preparation of fesoterodine and its pharmaceutically acceptable salt, specifically fesoterodine fumarate of formula (1). The invention relates to solid state forms of a novel salt of fesoterodine and process for the preparation thereof. The invention also relates to highly pure fesoterodine fumarate substantially free of impurity X at RRT 1.37. The invention also provides solid particles of pure fesoterodine fumarate wherein 90 volume-percent of the particles (D90) have a size of higher than 200 microns.

PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST

The present invention relates to novel and improved processes for the preparation of (r)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenylisobutyrate represented by the following structural formula-1 and its pharmaceutically acceptable salts thereof.

SOLID STATE FORMS OF FESOTERODINE INTERMEDIATES

Provided herein are novel solid state forms of fesoterodine intermediates, (R)-4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzoic acid and (R)-[4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-phenyl]-methanol, and processes for their preparation thereof. The solid state intermediates are useful for preparing fesoterodine or a pharmaceutically acceptable salt thereof in high purity.

Process for the Preparation of Fesoterodine

Disclosed herein is an improved, commercially viable and industrially advantageous process for the preparation of Fesoterodine or a pharmaceutically acceptable salt thereof in high yield and purity. Disclosed also herein is an improved and industrially advantageous optical resolution method of racemic (±)-N,N-Diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropylamine and use thereof for the preparation of Fesoterodine.